Payment overview · 2025
General Payments
$841.79
47 reported records · 11 companies
Healthcare provider profile · identity verified
Bryan Hale Merrick, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MC KENZIE, TN · NPI 1467455287
Verified facts
What the public records show
CMS Open Payments records show Bryan Hale Merrick, MD received $841.79 in general payments during 2025 across 47 reported records.
Amgen Inc. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $267.51 | 31.8% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $259.50 | 30.8% | 18 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.20 | 7.8% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $63.36 | 7.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.85 | 7.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.42 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.06 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.48 | 2.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.73 | 2.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.60 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.08 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $841.79 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $254.14 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $210.38 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $91.62 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $63.36 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.12 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.46 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.37 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.37 | 5 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 267 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
136 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
267 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
80 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
355 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1355 | 183 |
| Furosemide | Furosemide | 1292 | 147 |
| Potassium Chloride | Potassium Chloride | 1221 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 1003 | 174 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 926 | 204 |
| Omeprazole | Omeprazole | 881 | 137 |
| Famotidine | Famotidine | 773 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 738 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 722 | 104 |
| Losartan Potassium | Losartan Potassium | 721 | 116 |
| Gabapentin | Gabapentin | 718 | 138 |
| Metoprolol Tartrate | Metoprolol Tartrate | 680 | 89 |
| Lisinopril | Lisinopril | 673 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 533 | 71 |
| Trazodone Hcl | Trazodone Hcl | 526 | 83 |
| Simvastatin | Simvastatin | 498 | 86 |
| Metformin Hcl Er | Metformin Hcl | 479 | 91 |
| Tizanidine Hcl | Tizanidine Hcl | 460 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 444 | 61 |
| Mirtazapine | Mirtazapine | 409 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 401 | 36 |
| Carvedilol | Carvedilol | 400 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 370 | 41 |
| Sertraline Hcl | Sertraline Hcl | 356 | 40 |
| Eliquis | Apixaban | 355 | 40 |
| Donepezil Hcl | Donepezil Hcl | 332 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 330 | 71 |
| Citalopram Hbr | Citalopram Hydrobromide | 328 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 327 | 67 |
| Hydralazine Hcl | Hydralazine Hcl | 321 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 311 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 302 | 92 |
| Allopurinol | Allopurinol | 294 | 43 |
| Pregabalin | Pregabalin | 291 | 52 |
| Metformin Hcl | Metformin Hcl | 289 | 53 |
| Buspirone Hcl | Buspirone Hcl | 287 | 26 |
| Levetiracetam | Levetiracetam | 284 | 27 |
| Farxiga | Dapagliflozin Propanediol | 267 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 267 | 23 |
| Montelukast Sodium | Montelukast Sodium | 262 | 54 |
| Alprazolam | Alprazolam | 259 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 61 |
| Fluoxetine Hcl | Fluoxetine Hcl | 235 | 15 |
| Sucralfate | Sucralfate | 229 | 16 |
| Meloxicam | Meloxicam | 214 | 54 |
| Xarelto | Rivaroxaban | 212 | 23 |
| Divalproex Sodium | Divalproex Sodium | 202 | 17 |
| Baclofen | Baclofen | 201 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 200 | 49 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 194 | 28 |
| Prednisone | Prednisone | 193 | 50 |
| Lamotrigine | Lamotrigine | 191 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 188 | 85 |
| Warfarin Sodium | Warfarin Sodium | 182 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 178 | 21 |
| Glimepiride | Glimepiride | 166 | 38 |
| Lorazepam | Lorazepam | 166 | 37 |
| Ozempic | Semaglutide | 165 | 28 |
| Atenolol | Atenolol | 164 | 23 |
| Clonazepam | Clonazepam | 164 | 34 |
| Spironolactone | Spironolactone | 164 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 163 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 163 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 162 | 24 |
| Tramadol Hcl | Tramadol Hcl | 160 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 156 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 154 | 18 |
| Ezetimibe | Ezetimibe | 148 | 45 |
| Oxybutynin Chloride | Oxybutynin Chloride | 140 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 140 | 24 |
| Midodrine Hcl | Midodrine Hcl | 139 | suppressed |
| Myrbetriq | Mirabegron | 136 | suppressed |
| Memantine Hcl | Memantine Hcl | 132 | suppressed |
| Januvia | Sitagliptin Phosphate | 130 | 11 |
| Bumetanide | Bumetanide | 129 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 121 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 36 |
| Primidone | Primidone | 109 | suppressed |
| Bupropion Xl | Bupropion Hcl | 108 | 17 |
| Finasteride | Finasteride | 108 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 106 | suppressed |
| Digoxin | Digoxin | 103 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 101 | 21 |
| Meclizine Hcl | Meclizine Hcl | 97 | 23 |
| Jardiance | Empagliflozin | 94 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 24 |
| Cephalexin | Cephalexin | 83 | 34 |
| Amiodarone Hcl | Amiodarone Hcl | 80 | 13 |
| Trulicity | Dulaglutide | 80 | 13 |
| Diazepam | Diazepam | 78 | 19 |
| Dutasteride | Dutasteride | 78 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 76 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 74 | 13 |
| Ranolazine Er | Ranolazine | 73 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 70 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 70 | suppressed |
| Lovastatin | Lovastatin | 70 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 33 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 68 | suppressed |
| Mounjaro | Tirzepatide | 66 | suppressed |
| Aripiprazole | Aripiprazole | 65 | 12 |
| Azithromycin | Azithromycin | 64 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 15 |
| Ibuprofen | Ibuprofen | 62 | 23 |
| Methotrexate | Methotrexate Sodium | 62 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 62 | suppressed |
| Latanoprost | Latanoprost | 61 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 61 | suppressed |
| Fenofibrate | Fenofibrate | 60 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 59 | 20 |
| Fluconazole | Fluconazole | 58 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 25 |
| Nystatin | Nystatin | 57 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Cilostazol | Cilostazol | 56 | suppressed |
| Vraylar | Cariprazine Hcl | 56 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 55 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 55 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 55 | suppressed |
| Celecoxib | Celecoxib | 54 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 53 | suppressed |
| Olanzapine | Olanzapine | 52 | 11 |
| Novolog | Insulin Aspart | 51 | suppressed |
| Topiramate | Topiramate | 51 | 13 |
| Linzess | Linaclotide | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 14 |
| Methocarbamol | Methocarbamol | 46 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 45 | 13 |
| Nitroglycerin | Nitroglycerin | 45 | 28 |
| Vascepa | Icosapent Ethyl | 45 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | suppressed |
| Gemtesa | Vibegron | 44 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 43 | suppressed |
| Creon | Lipase/Protease/Amylase | 43 | suppressed |
| Cefdinir | Cefdinir | 41 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 34 |
| Folic Acid | Folic Acid | 41 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Risperidone | Risperidone | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Methadone Hcl | Methadone Hcl | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 28 |
| Levemir | Insulin Detemir | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 11 |
| Silodosin | Silodosin | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Acetylcysteine | Acetylcysteine | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 24 |
| Scopolamine | Scopolamine | 30 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | 11 |
| Risperidone Odt | Risperidone | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 26 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 25 | suppressed |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 18 |
| Valsartan | Valsartan | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 23 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Nystop | Nystatin | 22 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 17 |
| Lidocaine Hcl | Lidocaine Hcl | 21 | 11 |
| Metolazone | Metolazone | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 13 |
| Ramipril | Ramipril | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Caplyta | Lumateperone Tosylate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Paliperidone Er | Paliperidone | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Pirfenidone | Pirfenidone | 12 | suppressed |
| Rinvoq | Upadacitinib | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Aristada | Aripiprazole Lauroxil | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $841.79 · 47 records | Amgen Inc. | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, EVENITY, FANAPT, FARXIGA, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, UBRELVY, VRAYLAR, Veozah, YUPELRI, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error